Thousands of medical marijuana patients in the United States rely on the drug to alleviate a multitude of symptoms from cachexia to nerve pain; nevertheless, the Drug Enforcement Administration (DEA) still considers it a Schedule I controlled substance that has no accepted medical use.
Despite this law-enforcement-agency-approved “analysis,” doctors are conducting their own research. In Israel, the Meir Medical Center is recruiting Crohn’s Disease sufferers for a study on the ability of marijuana to treat the inflammatory bowel disease, which affects 400,000-600,000 North Americans.
In San Francisco, for more than five years, doctors at California Pacific Medical Center have been studying the effects of the marijuana compound cannabidiol (CBD) on metastatic cancer cells (i.e., very aggressive tumor cells). In their recently published large-scale animal trial, brain scans revealed the disruption of tumor cells after CBD was used to switch off a specific gene regulator.
These promising results left researchers optimistic and they believe that the findings warrant human trials. They will work to secure funding in the upcoming months for two trial groups, one for brain cancer and the other for breast cancer.
Will these and other studies finally convince our government that science, not myth, should dictate how we approach marijuana?